http://checkmateupdate.com/ WebOct 6, 2024 · The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year...
FDA Approves Nivolumab in Combination with Chemotherapy …
WebApr 1, 2024 · Conclusions: Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and … WebMay 17, 2024 · First-Line Therapy for Advanced Disease: CheckMate 649 “Based on early results showing the effect of immunotherapy, we’ve seen a series of first-line studies that were quickly up and running,” Dr. Mulcahy said. For the first-line treatment of advanced gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal … found co values without penalty
Checkmate! on the App Store
WebCheckMate 648 is a global phase 3 trial that evaluated the efficacy and safety of both an immune checkpoint inhibitor in combination with chemotherapy and a dual immune … WebAug 11, 2024 · Checkmate -649 is a Phase 3 randomized, multi-center, open-label study evaluating Opdivo plus chemotherapy or the Opdivo plus Yervoy combination compared to chemotherapy alone in patients with previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma. WebJan 22, 2024 · Follow-up data from the CheckMate 649 trial (NCT02872116) that were presented at the 2024 Gastrointestinal Cancers Symposium indicated that use of … found cozy sanctuary